199 related articles for article (PubMed ID: 33589521)
1. Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients.
Huber V; Di Guardo L; Lalli L; Giardiello D; Cova A; Squarcina P; Frati P; Di Giacomo AM; Pilla L; Tazzari M; Camisaschi C; Arienti F; Castelli C; Rodolfo M; Beretta V; Di Nicola M; Maio M; Del Vecchio M; de Braud F; Mariani L; Rivoltini L
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589521
[TBL] [Abstract][Full Text] [Related]
2. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Gaißler A; Bochem J; Spreuer J; Ottmann S; Martens A; Amaral T; Wagner NB; Claassen M; Meier F; Terheyden P; Garbe C; Eigentler T; Weide B; Pawelec G; Wistuba-Hamprecht K
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286306
[TBL] [Abstract][Full Text] [Related]
3. Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma.
Sheng IY; Diaz-Montero CM; Rayman P; Wei W; Finke JH; Kim JS; Pavicic PG; Lamenza M; Company D; Stephenson A; Campbell S; Haber G; Lee B; Mian O; Gilligan TD; Rini BI; Garcia JA; Grivas P; Ornstein MC
Target Oncol; 2020 Apr; 15(2):211-220. PubMed ID: 32207064
[TBL] [Abstract][Full Text] [Related]
4. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
[TBL] [Abstract][Full Text] [Related]
6. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM
Cancer Med; 2016 Oct; 5(10):2792-2799. PubMed ID: 27683208
[TBL] [Abstract][Full Text] [Related]
7. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
[TBL] [Abstract][Full Text] [Related]
8. Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
Sun SH; Benner B; Savardekar H; Lapurga G; Good L; Abood D; Nagle E; Duggan M; Stiff A; DiVincenzo MJ; Suarez-Kelly LP; Campbell A; Yu L; Wesolowski R; Howard H; Shah H; Kendra K; Carson WE
Front Immunol; 2021; 12():740890. PubMed ID: 34712230
[TBL] [Abstract][Full Text] [Related]
9. High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma.
Melief J; Pico de Coaña Y; Maas R; Fennemann FL; Wolodarski M; Hansson J; Kiessling R
Cancer Immunol Immunother; 2020 Apr; 69(4):513-522. PubMed ID: 31953577
[TBL] [Abstract][Full Text] [Related]
10. Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients.
Del Bianco P; Pinton L; Magri S; Canè S; Masetto E; Basso D; Padovan M; Volpin F; d'Avella D; Lombardi G; Zagonel V; Bronte V; Della Puppa A; Mandruzzato S
Front Immunol; 2021; 12():809826. PubMed ID: 35069595
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
Apodaca MC; Wright AE; Riggins AM; Harris WP; Yeung RS; Yu L; Morishima C
J Immunother Cancer; 2019 Aug; 7(1):230. PubMed ID: 31462270
[TBL] [Abstract][Full Text] [Related]
12. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Meyer C; Cagnon L; Costa-Nunes CM; Baumgaertner P; Montandon N; Leyvraz L; Michielin O; Romano E; Speiser DE
Cancer Immunol Immunother; 2014 Mar; 63(3):247-57. PubMed ID: 24357148
[TBL] [Abstract][Full Text] [Related]
13. Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC.
Huang H; Zhang G; Li G; Ma H; Zhang X
Tumour Biol; 2015 Sep; 36(10):7987-96. PubMed ID: 25967454
[TBL] [Abstract][Full Text] [Related]
14. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
Ferrucci PF; Ascierto PA; Pigozzo J; Del Vecchio M; Maio M; Antonini Cappellini GC; Guidoboni M; Queirolo P; Savoia P; Mandalà M; Simeone E; Valpione S; Altomonte M; Spagnolo F; Cocorocchio E; Gandini S; Giannarelli D; Martinoli C
Ann Oncol; 2016 Apr; 27(4):732-8. PubMed ID: 26802161
[TBL] [Abstract][Full Text] [Related]
15. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival.
Fallah J; Diaz-Montero CM; Rayman P; Wei W; Finke JH; Kim JS; Pavicic PG; Lamenza M; Dann P; Company D; Stephenson A; Campbell S; Haber G; Lee B; Mian O; Gilligan T; Garcia JA; Rini B; Ornstein MC; Grivas P
Clin Genitourin Cancer; 2020 Dec; 18(6):500-508. PubMed ID: 32340875
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic Value of CD14
Wu CX; Qiang M; Hao JQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):816-819. PubMed ID: 31204937
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy.
Tomela K; Pietrzak B; Galus Ł; Mackiewicz J; Schmidt M; Mackiewicz AA; Kaczmarek M
Cells; 2023 Mar; 12(5):. PubMed ID: 36899926
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides.
Argyropoulos KV; Pulitzer M; Perez S; Korkolopoulou P; Angelopoulou M; Baxevanis C; Palomba ML; Siakantaris M
Clin Transl Oncol; 2020 Jul; 22(7):1059-1066. PubMed ID: 31696413
[TBL] [Abstract][Full Text] [Related]
20. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.
Perez C; Botta C; Zabaleta A; Puig N; Cedena MT; Goicoechea I; Alameda D; San José-Eneriz E; Merino J; Rodríguez-Otero P; Maia C; Alignani D; Maiso P; Manrique I; Lara-Astiaso D; Vilas-Zornoza A; Sarvide S; Riillo C; Rossi M; Rosiñol L; Oriol A; Blanchard MJ; Rios R; Sureda A; Martin J; Martinez R; Bargay J; de la Rubia J; Hernandez MT; Martinez-Lopez J; Orfao A; Agirre X; Prosper F; Mateos MV; Lahuerta JJ; Blade J; San-Miguel JF; Paiva B
Blood; 2020 Jul; 136(2):199-209. PubMed ID: 32325491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
